Status:
RECRUITING
Research on Severe Asthma
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Adult Severe Asthma Patients Treated in France
Eligibility:
All Genders
18+ years
Brief Summary
The French Society for Respiratory diseases (SPLF), through its Asthma and Allergy working group (G2A), wishes to set up a national cohort of severe asthma patients to describe this population and the...
Detailed Description
Severe asthma is defined by poorly controlled disease despite treatment with high doses of inhaled corticosteroids, in combination with at least a long acting beta agonist, after optimal management fo...
Eligibility Criteria
Inclusion
- \- Patient with severe asthma : Meeting the definition of ATS-ERS: which requires a combination of high dose CSI and B2LDA.
- Or receiving level 5 support (initiating treatment or already treated) :
- Long-term oral corticosteroids (\> 6 months in the year prior to inclusion)
- And / or monoclonal antibody
- And / or bronchial thermoplasty
- And / or other complex costs corresponding to the level 5 treatments
- Consultant or hospitalized in one of the centers participating in RAMSES study
Exclusion
- Patient does not accept the recording of his data in the cohort
- Patient not benefiting from health insurance coverage
- Patient under curatorship or tutorship
Key Trial Info
Start Date :
September 10 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2025
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT04077528
Start Date
September 10 2019
End Date
September 1 2025
Last Update
January 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Bichat
Paris, France, 75877